Cramer says the growing popularity of weight loss drugs brings new investing opportunities

But with the market as a whole seeing a rebound, Cramer said investors can now turn their attention to stocks that could see gains because of these drugs.

“I think we should start to appreciate the good, and that’s what I want to go over,” he said. “Because if you really believe tons of people will take these weight loss medications, to the point where it’ll have a transformational impact on the economy, well that’s going to create lots of winners, too.”

First, investors could simply buy shares of the companies that make these medications. To Cramer, two companies own the GLP-1 space — Eli Lilly $Eli Lilly and Co(LLY.US)$ and Novo Nordisk $Novo-Nordisk A/S(NVO.US)$ — and their stocks have already had significant runs. But Cramer said he thinks they could see more gains because these drugs may be able to treat conditions besides obesity and diabetes, such as heart disease, kidney disease and alcoholism.

But there are several less obvious GLP-1 plays, like companies known for producing meat and high-protein foods such as Tyson Foods $Tyson Foods(TSN.US)$ or Hormel Foods $Hormel Foods(HRL.US)$ . Cramer said GLP-1 drugs can cause patients to lose muscle as well as fat, so doctors are encouraging them to consume more protein.